Largest Pharmaceuticals, Biotechnology & Life Sciences Companies By Total Asset

Total Asset
Total AssetEfficiencyMarket RiskExp Return
1TAK Takeda Pharmaceutical Co
15.11 T
(0.17)
 0.90 
(0.16)
2RDY Dr Reddys Laboratories
387.52 B
(0.16)
 1.28 
(0.21)
3NVO Novo Nordisk AS
314.49 B
(0.22)
 1.77 
(0.39)
4PFE Pfizer Inc
226.5 B
(0.14)
 1.37 
(0.20)
5JNJ Johnson Johnson
167.56 B
(0.12)
 0.76 
(0.09)
6ABBV AbbVie Inc
134.71 B
(0.11)
 1.98 
(0.22)
7SNY Sanofi ADR
126.46 B
(0.21)
 1.20 
(0.25)
8MRK Merck Company
106.67 B
(0.24)
 1.10 
(0.26)
9AZN AstraZeneca PLC ADR
101.12 B
(0.33)
 1.44 
(0.48)
10NVS Novartis AG ADR
99.94 B
(0.22)
 0.97 
(0.21)
11TMO Thermo Fisher Scientific
98.73 B
(0.21)
 1.20 
(0.25)
12AMGN Amgen Inc
97.15 B
(0.12)
 1.57 
(0.18)
13BMY Bristol Myers Squibb
95.16 B
 0.16 
 1.99 
 0.33 
14LLY Eli Lilly and
64.01 B
(0.19)
 1.81 
(0.35)
15GILD Gilead Sciences
62.12 B
 0.18 
 1.42 
 0.25 
16GSK GlaxoSmithKline PLC ADR
59.01 B
(0.23)
 1.54 
(0.35)
17VTRS Viatris
47.69 B
 0.09 
 2.27 
 0.20 
18TEVA Teva Pharma Industries
43.48 B
(0.07)
 1.77 
(0.12)
19GMAB Genmab AS
35.29 B
(0.30)
 1.48 
(0.44)
20HLN Haleon plc
34.05 B
(0.07)
 0.95 
(0.06)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.